trending Market Intelligence /marketintelligence/en/news-insights/trending/KcHbSpFZ-QWKuFngqYiu3A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Omeros raises $57.5M from stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Omeros raises $57.5M from stock offering

Omeros Corp. said it raised $57.5 million after underwriters of its previously announced offering fully exercised their overallotment option.

The Seattle-based pharmaceutical company sold 4,389,311 shares at $13.10 apiece, including the additional 572,518 shares as part of underwriters' overallotment option.

Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering, which closed Dec. 9.

Omeros hopes to use the net proceeds for general corporate purposes, capital expenditures and to fund its products' clinical and preclinical trials.

Earlier this year, a European Medicines Agency committee backed Omeros' OMS721 for the treatment of a life-threatening complication of stem cell transplant called hematopoietic stem cell transplant-associated thrombotic microangiopathy.

The company is also seeking U.S. approval of the drug.